endpoint introduces PULSE™ 3.0 Platform for IRT Systems in Clinical Trials

Share Article

PULSE enables highly customized IRT trial design while maintaining endpoint’s signature 30-Day delivery timeline

endpoint Clinical, Inc., a leading provider of Interactive Response Technology (IRT) systems via phone (IVRS), web (IWRS) and mobile (IMRS) for global clinical trials, today announced the launch of its next-generation PULSE 3.0 platform. The enhanced PULSE platform provides highly customized configuration and deployment of complex trial designs in a rapid and repeatable manner unmatched in the clinical trials industry.

Speaking from the company’s San Francisco HQ, endpoint’s CEO and co-founder Jonathan Dole cited the redesign of PULSE as a significant milestone in the company’s development and growth:

“endpoint’s PULSE revolutionized the IRT industry in 2010 by enabling drastic time-reduction for IRT system deployment, while providing highly customized trial designs. With the introduction of PULSE 3.0, endpoint’s users have unprecedented access to a robust array of IRT trial design features and functionality through an intuitive interface, making endpoint’s PULSE, the clinical trial industry’s most robust configurable IRT solution.”

The upgraded platform will be demonstrated at the annual Drug Information Association (DIA) conference on June 16th in San Diego, CA, where endpoint will have a booth (booth #2125). Clients can also learn more about PULSE 3.0 at (http://www.endpointclinical.com).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ciaran Donnelly

Ciaran Donnelly
Visit website